Brokerages Anticipate Pacira BioSciences, Inc. (NASDAQ:PCRX) Will Post Earnings of $0.91 Per Share

Wall Street analysts predict that Pacira BioSciences, Inc. (NASDAQ:PCRXGet Rating) will report $0.91 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for Pacira BioSciences’ earnings, with the highest EPS estimate coming in at $1.04 and the lowest estimate coming in at $0.78. Pacira BioSciences reported earnings per share of $0.77 in the same quarter last year, which suggests a positive year-over-year growth rate of 18.2%. The company is expected to announce its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Pacira BioSciences will report full-year earnings of $3.90 per share for the current year, with EPS estimates ranging from $3.42 to $4.48. For the next financial year, analysts expect that the company will post earnings of $5.39 per share, with EPS estimates ranging from $4.51 to $5.98. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Pacira BioSciences.

Pacira BioSciences (NASDAQ:PCRXGet Rating) last issued its quarterly earnings results on Wednesday, May 4th. The company reported $0.64 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.19). Pacira BioSciences had a return on equity of 15.17% and a net margin of 6.62%. The business had revenue of $157.99 million during the quarter, compared to analysts’ expectations of $155.08 million. During the same quarter in the previous year, the company posted $0.37 EPS. The company’s quarterly revenue was up 32.7% on a year-over-year basis.

A number of research analysts have recently weighed in on the company. TheStreet lowered Pacira BioSciences from a “b-” rating to a “c” rating in a research report on Thursday, February 24th. StockNews.com assumed coverage on Pacira BioSciences in a research report on Thursday, March 31st. They set a “hold” rating for the company. Wedbush restated a “buy” rating and set a $94.00 price objective (down previously from $97.00) on shares of Pacira BioSciences in a research report on Saturday, February 26th. HC Wainwright raised their price objective on Pacira BioSciences from $86.00 to $90.00 and gave the company a “buy” rating in a research report on Friday, February 25th. Finally, Northland Securities raised their price objective on Pacira BioSciences from $61.00 to $67.00 in a research report on Tuesday, March 1st. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $80.63.

In other Pacira BioSciences news, Director Gary W. Pace sold 1,359 shares of the firm’s stock in a transaction dated Tuesday, March 1st. The shares were sold at an average price of $67.75, for a total value of $92,072.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mark Froimson sold 1,000 shares of the firm’s stock in a transaction dated Monday, May 9th. The stock was sold at an average price of $59.37, for a total transaction of $59,370.00. Following the completion of the sale, the director now directly owns 4,908 shares of the company’s stock, valued at approximately $291,387.96. The disclosure for this sale can be found here. In the last quarter, insiders sold 67,557 shares of company stock valued at $4,955,474. 5.20% of the stock is currently owned by company insiders.

Several institutional investors have recently bought and sold shares of the company. Walleye Capital LLC raised its stake in shares of Pacira BioSciences by 17.3% during the first quarter. Walleye Capital LLC now owns 135,027 shares of the company’s stock valued at $10,305,000 after acquiring an additional 19,930 shares in the last quarter. First National Bank of Omaha raised its stake in Pacira BioSciences by 7.2% in the first quarter. First National Bank of Omaha now owns 25,140 shares of the company’s stock worth $1,919,000 after buying an additional 1,688 shares in the last quarter. Phocas Financial Corp. purchased a new stake in Pacira BioSciences during the first quarter worth $7,132,000. Neuberger Berman Group LLC increased its holdings in shares of Pacira BioSciences by 109.9% in the 1st quarter. Neuberger Berman Group LLC now owns 18,489 shares of the company’s stock valued at $1,411,000 after acquiring an additional 9,680 shares during the period. Finally, Van Hulzen Asset Management LLC raised its position in shares of Pacira BioSciences by 1.4% in the 1st quarter. Van Hulzen Asset Management LLC now owns 12,742 shares of the company’s stock worth $972,000 after acquiring an additional 178 shares in the last quarter.

Shares of Pacira BioSciences stock traded up $2.26 during trading on Friday, reaching $64.44. 276,082 shares of the stock traded hands, compared to its average volume of 528,902. The company has a market capitalization of $2.93 billion, a price-to-earnings ratio of 76.72 and a beta of 0.88. The business has a fifty day simple moving average of $70.87 and a two-hundred day simple moving average of $65.00. The company has a debt-to-equity ratio of 1.03, a current ratio of 2.19 and a quick ratio of 1.85. Pacira BioSciences has a 52-week low of $45.05 and a 52-week high of $82.16.

About Pacira BioSciences (Get Rating)

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves.

See Also

Get a free copy of the Zacks research report on Pacira BioSciences (PCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pacira BioSciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.